KZIA - Kazia Therapeutics Shares Are Jumping Today: Successful Study For Brain Cancer Treatment | Benzinga
Kazia Therapeutics Limited (NASDAQ:KZIA) released results on Wednesday from the GBM-AGILE Phase 2/3 study that included an evaluation of paxalisib versus standard of care (SOC) for patients with glioblastoma, a type of brain cancer.
Shares are trading higher on a strong session volume of 106.49 million, as per data from Benzinga Pro.
There were 313 newly diagnosed unmethylated (NDU) patients and recurrent patients randomized in Stage 1 to either a paxalisib treatment arm (60 mg/day) or the SOC concurrent control arm from January 2021 to May 2022.
“We are excited to have shown a 3.8-month improvement in overall survival, an approximate 33% improvement, for newly diagnosed unmethylated patients with GBM compared to the concurrent standard of ...